Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02374099
Title Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant
Recruitment Terminated
Gender female
Phase Phase II
Variant Requirements No
Sponsors Celgene Corporation
Indications

Her2-receptor negative breast cancer

Therapies

Azacitidine

Fulvestrant

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | DEU | BEL


No variant requirements are available.